

DAFTAR PUSTAKA

- Andriztina I, *et al.* 2014. Gangguan Pendengaran dan Keseimbangan pada Penderita Tuberkulosis yang mendapat Pengobatan Antituberkulosis Kategori 1 dan 2. *Jurnal Kesehatan Masyarakat Nasional*. 8(8): 430-436.
- Ballenger, J., 1997. Penyakit telinga, hidung, tenggorok, kepala dan leher. Alih bahasa: Staf pengajar FKUI RSCM. 13: 105-109
- Campbell, K., Peck, J., Lee, K., 2008. *Audiology. Essential Otolaryngology Head & Neck Surgery. 9th ed*: 24-69.
- Chambers., Henry, F., 2007. Senyawa antimikroba aminoglikosida. Dasar farmakologi terapi. EGC. 2: 1195-1204.
- Dhingra, P., 2006. *Peripheral receptors and physiology of auditory and vestibular systems. Elsevier health sciences*. 4: 14-17.
- Duggal, P., Sarkar, M. 2007. *Audiologic monitoring of multidrug resistant tuberculosis patients on aminoglycoside treatment with long term follow up. BMC Ear Nose and Throat Disord*. 7(5): 1-7.
- Durant, J., Campbell, K., Fausti, S., 2009. *American Academy of Audiology Position Statment and Clinical Practice Guidelines*. Washington, American Academy of Audiology.
- Gelfand, S., 2010. *Hearing an introduction to psychological and physiological acoustics. Informa healthcare*. 5: 72-86.
- Gillespie, P., 2006. *Hair cell function. Otolaryngology basic science and clinical review*: 332-338.
- Heijden, A., *et al.*, 2007. *Optimal furosemid therapy in critically infants. Erasmus University Rotterdam*: 15-16.
- Huth, M.E., Ricci, A.J., Cheng, A.G., 2011. *Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection*. *Int J Otolaryngol*. 20(11): 1-19.
- Ismulat, R., *et al.*, 2019. Prevalensi Ototoksik pada Pasien Tuberkulosis Resisten Obat dan Faktor yang Berhubungan di Rumah Sakit Umum Pusat Persahabatan. *J Respir Indo*. 39(3):180-195.
- Kranzer, K., Elamin, W.F., Cox, H., Seddon, J.A., Ford, N., Drobniewski, F., 2015. *A systematic review and meta-analysis of the efficacy and safety of N-acetylsisteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. Thorax*. 70(11): 1070-7.
- Kocyigit, I., Tokgoz, B., Ucar, C., Somdas, M., Unal, A., Vural, A., Sipahioglu, M., Oymak, O., Utas, C., 2015. *Protective effect of N-acetylcysteine from*

drug-induced ototoxicity in uraemic patients with CAPD peritonitis. Nephrol Dial Transplant. 26(12): 4073-8.

- Lavoie, K. J., 2003. *High Frequency Pure Tone Audiometry and High Frequency Distortion Product Otoacoustic Emissions: A Correlational Analysis*, Oregon: Portland State University.
- Magdalena, S., *et al.* 2013. *Relationship between kanamycin injection treatment and evaluation of hearing loss in MDR-TB patients in Dr. Moewardi Hospital. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Sebelas Maret Surakarta.*
- Martin, D. *et al.*, 2005. *Audiological monitoring of patient receiving ototoxicity drugs. American Speech language Hearing Association:* 2-4.
- Miller., Monica, L., Blakenship., Crystal., 2010. *Drug-induced disease. ASHP:* 1049-1054.
- Møller, A., 2003. *Sensory systems anatomy and physiology. Elsevier Science:* 272-304.
- Neyrolles, O., Murci, L.Q., 2009. *Sexual inequality in tuberculosis. Plosmed.* 6(12): 1-6.
- Nugrahaeni, D. K., Malik, U. S., 2015. Analisis penyebab resistensi obat anti tuberkulosis. *Jurnal Kesehatan Masyarakat.* 1: 8-15.
- Paul, R., 2018. *The threat of multidrug-resistant tuberculosis. J Global Infect Dis.* 10: 119-120.
- Pawlowski, K., 2004. *Anatomy and physiology of the cochlea. BC Decker Inc:* 1-15.
- Peloquin, C.A., Berning, S.E., Nitta, A.T., *et al*, 2004. *Aminoglycoside toxicity: daily versus thrice weekly dosing for treatment of mycobacterial diseases. CID.* 38: 1538-1544.
- Quelapio, M. *et al.*, 2019. *Guide to detect and manage hearing loss during the management of multidrug-resistant tuberculosis.* 1: 1-10.
- Ramma, L., Ibekwe, T.S., 2012. *Cochleo-vestibular clinical findings among drug resistant Tuberculosis Patients on therapy-a pilot study. Int Arch Med,* 5(3): 1-5.
- Reiter, R., Tan, D., Korkmaz, A., Fuentes, B., 2011. *Drug-mediated ototoxicity and tinnitus Alleviation with melatonin. Journal of Physiology and Pharmacology.* 62: 1-7.
- Reviono, K.P., Eko, V., Pakiding, H., Nurwidiastih, D., 2014. *Multidrug resistant tuberculosis (MDR-TB): tinjauan epidemiologi dan faktor risiko efek samping obat anti tuberkulosis.* 46(4).

- Rybak, L.P., Whitworth, C.A., 2005. *Ototoxicity: therapeutic opportunities. Drug Discov Today*. 10(19) 1313–1321.
- Sagwa, E.L., Ruswa, N., Mavhunga, F., Rennie, T., Leufkens, H., Teeuwisse A.K.M., 2015. *Comparing amikacin and kanamycin induced hearing loss in multi drug resistant tuberculosis treatment under programmatic condition in a namibian retrospective cohort. BMC Pharmacol Toxicol*. 16(36): 1-9.
- Sharma, V., Bhagat, S., Verma, B., Singh, R., Singh, S., 2016. *Audiological evaluation of patients taking kanamycin for multidrug resistant tuberculosis. Iran J Otorhinolar*. 28(3): 203-208.
- Soetirto, Indro, Bramantyo & Bashirudin, 2001. Gangguan pendengaran akibat obat ototoksik. Buku ajar ilmu kesehatan telinga hidung tenggorok kepala leher. 5: 53-56.
- Sturdy, A., Goodman, A., Jose, R.J., Loyse, A., *et al.* 2011. *Multidrug resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother*. 66: 1-6.
- Sudipta, I.M., 2015. Gangguan pendengaran pada pasien dengan multidrug resistant tuberkulosis. Denpasar, SMF Ilmu Kesehatan THT-KL Fakultas Kedokteran Universitas Udayana/RSUP Sanglah Denpasar.
- Widiastuti, E. N., Subronto., Dibyo, P., 2017. Determinan kejadian *multi-drug resistant tuberculosis* di rumah sakit Dr. Sardjito Yogyakarta. *BKM Journal of Community Medicine and Public Health*, 33(7): 325-330.
- Yulianti., Sally, M., 2015. Gangguan pendengaran penderita tuberkulosis *multidrug resistant*. *ORLI*. 45(2): 83-89.
- Yuni, I. D. A. M. A., 2016. *Relationship Between TB Treatment Phase and Knowledge of MDR-TB with TB Patient's Compliance*. *Jurnal Berkala Epidemiologi*. 4(3): 301-12.